Research Analysts Set Expectations for ELEV FY2025 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Investment analysts at HC Wainwright increased their FY2025 EPS estimates for shares of Elevation Oncology in a report released on Tuesday, June 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.71) per share for the year, up from their prior estimate of ($0.73). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Elevation Oncology’s Q4 2025 earnings at ($0.17) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.46) EPS and FY2029 earnings at ($0.39) EPS.

Elevation Oncology (NASDAQ:ELEV) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04).

Several other equities research analysts have also issued reports on the stock. Stephens reiterated an “equal weight” rating and set a $1.00 target price (down from $5.00) on shares of Elevation Oncology in a research report on Monday, March 24th. Citizens Jmp cut shares of Elevation Oncology from an “outperform” rating to a “market perform” rating in a research report on Friday, March 21st. Leerink Partners downgraded shares of Elevation Oncology from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $9.00 to $1.00 in a report on Friday, March 21st. TD Cowen cut Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research note on Monday. Finally, Piper Sandler downgraded Elevation Oncology from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $10.00 to $0.70 in a research report on Friday, March 21st. Eleven investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.39.

Elevation Oncology Price Performance

Shares of NASDAQ:ELEV opened at $0.38 on Thursday. The company has a 50 day moving average of $0.33 and a 200 day moving average of $0.49. The company has a current ratio of 17.77, a quick ratio of 17.77 and a debt-to-equity ratio of 0.45. The stock has a market cap of $22.52 million, a P/E ratio of -0.46 and a beta of 1.43. Elevation Oncology has a 12 month low of $0.22 and a 12 month high of $3.45.

Institutional Trading of Elevation Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC boosted its position in Elevation Oncology by 33.9% during the 4th quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after acquiring an additional 15,560 shares in the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Elevation Oncology by 294.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 69,105 shares of the company’s stock worth $39,000 after purchasing an additional 51,590 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Elevation Oncology during the 4th quarter worth $36,000. JPMorgan Chase & Co. boosted its position in Elevation Oncology by 194.1% during the fourth quarter. JPMorgan Chase & Co. now owns 180,375 shares of the company’s stock valued at $101,000 after purchasing an additional 119,041 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Elevation Oncology by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 1,157,572 shares of the company’s stock valued at $651,000 after purchasing an additional 47,487 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.